Fusion Pharmaceuticals Inc. (NASDAQ:FUSN) Receives $20.25 Consensus Target Price from Analysts

Shares of Fusion Pharmaceuticals Inc. (NASDAQ:FUSN – Get Free Report) have earned a consensus rating of “Hold” from the fourteen analysts that are presently covering the firm, MarketBeat reports. Thirteen equities research analysts have rated the stock with a hold rating and one has issued a buy rating on the company. The average 12 month […]

Related Keywords

New York ,United States ,China ,Canada ,Raymond James ,William Blair ,Leerink Partnrs ,Royal Bank ,Fusion Pharmaceuticals Inc ,Fusion Pharmaceuticals ,Fusion Pharmaceuticals Stock Performance ,Institutional Investors Weigh In On Fusion Pharmaceuticals ,China Universal Asset Management Co ,York State Common Retirement Fund ,Fusion Pharmaceuticals Company Profile ,Analyst Recommendations For Fusion Pharmaceuticals ,Gamco Investors ,Tower Research Capital ,Nasdaq ,News Ratings For Fusion Pharmaceuticals Daily ,Get Free Report ,Research Capital ,Universal Asset Management ,Get Free ,Pharmaceuticals Inc ,Fusion Pharmaceuticals Daily ,